Talecris Biotherapeutics, a biopharmaceutical company has plans to lift as much as $894 million via initial public offerings.

As per the Securities and Exchange Commission filing, the North California-based company aims to sell 44.7 million shares at $18 to $20 a share.

In case Talecris Biotherapeutics is able to sell at the high end of its range, it is going to be the largest IPO so far in the running year. Twenty-one U. S. companies have already gone public this year.

It was informed that Talecris will utilize the proceeds from the IPO to pay off debt.

The company, which employs over 4,700 workers worldwide, specializes in plasma-derived protein therapies for a number of diseases.

Talecris has posted $747.4 million in revenue for the first half of 2009, up 20 per cent as compared with the same period of 2008. Company pocketed profit worth $116.7 million against $19 million last year.

Talecris Biotherapeutics is facing competition from Australian biopharmaceutical company CSL Ltd.